ICON Public’s (ICLR) “Buy” Rating Reiterated at Truist Financial

ICON Public (NASDAQ:ICLR)‘s stock had its “buy” rating reissued by analysts at Truist Financial in a report released on Wednesday,Benzinga reports. They currently have a $284.00 price target on the medical research company’s stock, down from their previous price target of $295.00. Truist Financial’s price target suggests a potential upside of 39.48% from the company’s current price.

ICLR has been the subject of several other reports. Barclays decreased their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. StockNews.com cut shares of ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Leerink Partners restated an “outperform” rating and set a $255.00 price objective (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. The Goldman Sachs Group reduced their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $289.10.

ICON Public Trading Up 0.2 %

NASDAQ:ICLR traded up $0.35 during trading hours on Wednesday, hitting $203.61. The stock had a trading volume of 39,883 shares, compared to its average volume of 754,279. The business’s 50 day moving average is $230.58 and its 200-day moving average is $284.89. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The company has a market cap of $16.80 billion, a price-to-earnings ratio of 22.70, a P/E/G ratio of 1.57 and a beta of 1.21. ICON Public has a one year low of $183.38 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the business posted $3.10 EPS. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. Sell-side analysts anticipate that ICON Public will post 13.42 EPS for the current fiscal year.

Institutional Trading of ICON Public

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public during the 2nd quarter valued at $54,000. EverSource Wealth Advisors LLC raised its position in ICON Public by 39.2% during the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of ICON Public by 119.6% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 226 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the last quarter. Finally, Crestwood Advisors Group LLC bought a new position in ICON Public in the second quarter valued at about $288,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.